LRRK2 in Parkinson's disease: biochemical functions
- PMID: 19804416
- DOI: 10.1111/j.1742-4658.2009.07341.x
LRRK2 in Parkinson's disease: biochemical functions
Abstract
Leucine-rich repeat kinase 2 (LRRK2) is a large, complex, multidomain protein containing kinase and GTPase enzymatic activities and multiple protein-protein interaction domains. Mutations linked to autosomal dominant forms of Parkinson's disease result in amino acid changes throughout the protein and alterations in both its enzymatic properties and interactions. The best characterized mutation to date, G2019S, leads to increased kinase activity, and mutations in the GTPase domain, such as R1441C and R1441G, have also been reported to influence kinase activity. Therefore, an examination of LRRK2's properties as a kinase is important for understanding the mechanisms underlying the disorder and has the potential to lead to therapeutics. These findings also suggest that there may be complex interplay between the functional domains of LRRK2. Here, we review LRRK2's biochemical functions based on structural and kinetic studies of the enzymatic domains, its potential substrates and the role of its interactions. Despite the field's embryonic understanding of the true relevance of these substrates and interactions, initial studies are providing clues with respect to its pathophysiological functions. Together, these findings should increase our understanding of mechanisms underlying Parkinson's disease and place LRRK2 as a unique molecular target for effective therapeutic development.
Similar articles
-
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.BMB Rep. 2010 Apr;43(4):233-44. doi: 10.5483/bmbrep.2010.43.4.233. BMB Rep. 2010. PMID: 20423607 Review.
-
LRRK2 in Parkinson's disease: protein domains and functional insights.Trends Neurosci. 2006 May;29(5):286-93. doi: 10.1016/j.tins.2006.03.006. Epub 2006 Apr 17. Trends Neurosci. 2006. PMID: 16616379 Review.
-
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.J Neurochem. 2007 Oct;103(1):238-47. doi: 10.1111/j.1471-4159.2007.04743.x. Epub 2007 Jul 10. J Neurochem. 2007. PMID: 17623048 Free PMC article.
-
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.Biochem Soc Trans. 2012 Oct;40(5):1074-9. doi: 10.1042/BST20120093. Biochem Soc Trans. 2012. PMID: 22988868 Free PMC article. Review.
-
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949. J Neurosci Res. 2009. PMID: 19025767 Free PMC article. Review.
Cited by
-
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.Hum Mol Genet. 2011 Nov 1;20(21):4209-23. doi: 10.1093/hmg/ddr348. Epub 2011 Aug 9. Hum Mol Genet. 2011. PMID: 21828077 Free PMC article.
-
LRRK2 autophosphorylation enhances its GTPase activity.FASEB J. 2016 Jan;30(1):336-47. doi: 10.1096/fj.15-277095. Epub 2015 Sep 22. FASEB J. 2016. PMID: 26396237 Free PMC article.
-
Evaluation of Models of Parkinson's Disease.Front Neurosci. 2016 Jan 19;9:503. doi: 10.3389/fnins.2015.00503. eCollection 2015. Front Neurosci. 2016. PMID: 26834536 Free PMC article. Review.
-
Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.Hum Mol Genet. 2015 Sep 15;24(18):5299-312. doi: 10.1093/hmg/ddv249. Epub 2015 Jun 29. Hum Mol Genet. 2015. PMID: 26123485 Free PMC article.
-
GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.Front Biosci (Elite Ed). 2012 Jun 1;4(7):2365-77. doi: 10.2741/e548. Front Biosci (Elite Ed). 2012. PMID: 22652643 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical